Recent Updates
Recently added Catalysts
NVCR Negative Sentiment Score: 25/100

NovoCure Limited: Please contact the Portnoy Law Firm to recover your losses; August 18 2023 deadline

Key Takeaway: NovoCure Limited (NASDAQ: NVCR) is facing a lawsuit that claims the company made false and misleading statements regarding the LUNAR study data. Investors who purchased securities between January 5, 2023, and June 5, 2023, are being advised to contact the Portnoy Law Firm for a review of their legal rights and options to recover losses. The lawsuit suggests that the data’s reliability in demonstrating clinical efficacy was compromised, potentially impacting the company’s regulatory prospects and operations negatively.

Market Sentiment Analysis

CONCERNS & RISKS

  • Lawsuit filed alleges false and misleading statements by the company.
  • Concerns regarding the accuracy of LUNAR study data exposure.
  • Regulatory prospects and overall operations are likely negatively affected.

Full Press Release Details

Investors can contact the law firm at no cost to learn more about recovering their losses
​LOS ANGELES, July 24, 2023 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises NovoCure Limited (“NovoCure” or the “Company”) (NASDAQ: NVCR) investors that a lawsuit filed on behalf of investors that purchased NovoCure securities between January 5, 2023 to June 5, inclusive (the “Class Period”)
Investors are encouraged to contact attorney Lesley F. Portnoy, by phone 844-767-8529 or email: lesley@portnoylaw.com, to discuss their legal rights, or click here to join the case via www.portnoylaw.com. The Portnoy Law Firm can provide a complimentary case evaluation and discuss investors’ options for pursuing claims to recover their losses.
The complaint asserts that the defendants engaged in false and/or deceptive statements and/or omitted important information, claiming the following:
The Company concealed the true nature of the LUNAR study data, which involved a relatively small percentage of participants who were receiving standard of care therapy.
Consequently, the reliability of the data in demonstrating clinical efficacy was significantly compromised.
The disclosure of this information had a reasonable likelihood of negatively affecting the Company's regulatory prospects and overall operations.
As a result, the Company's public statements made during the relevant times were materially false and misleading.
The allegations suggest that the defendants misrepresented the LUNAR study data and its impact, leading to potential negative consequences for the Company's regulatory prospects and operations.
Please visit our website to review more information and submit your transaction information.
The Portnoy Law Firm represents investors in pursuing claims against caused by corporate wrongdoing. The Firm’s founding partner has recovered over $5.5 billion for aggrieved investors. Attorney advertising. Prior results do not guarantee similar outcomes.
Lesley F. Portnoy, Esq.
Admitted CA and NY Bar
Attorney Advertising

Tags

Frequently Asked Questions

How can NovoCure investors contact the firm?

Investors can reach the Portnoy Law Firm by phone at 844-767-8529 or email lesley@portnoylaw.com.

What period does the NovoCure investor lawsuit cover?

The lawsuit covers NovoCure securities purchased between January 5, 2023, and June 5, 2023.

What is the complaint against NovoCure about?

The complaint alleges that NovoCure concealed critical data from the LUNAR study, compromising its reliability.

What are the potential consequences for NovoCure?

The allegations suggest possible negative impacts on NovoCure's regulatory prospects and overall operations.

Is the case evaluation offered by the law firm free?

Yes, the Portnoy Law Firm offers a complimentary case evaluation for investors.

Last updated: Jul 24, 2023